Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant for endocrine therapy-associated vasomotor symptoms in women with or at high risk for hormone receptor-positive breast cancer
2022-000095-18Phase 3Active
- Sponsor
- Bayer Consumer Health
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Elinzanetant with Placebo (2 arms). Primary endpoint: Mean change in frequency of moderate to severe hot flash from baseline to Week 4. Started Jul 2022; status: active.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on 2022-000095-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000095-18.